| abstract |
Antibodies that specifically bind the extracellular domain of IRT A3 immunoglobulin superfamily receptor translocation associated or that specifically bind the extracellular domain of IRTA5 are disclosed herein. Antibodies ' that specifically bind to IRT A3 do not specifically bind IRTAl, IRT A2, IRTA4, IRTA5, or IRTA6. Antibodies that specifically bind to IRTA5 do not specifically bind IRTAl, IRTA2, IRTA3, IRTA4, or IRTA6. The antibodies can be conjugated to effector molecules, including detectable labels, radionucleotides, toxins and chemotherapeutic agents. Nucleic acid molecules encoding these antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. Methods also are provided for detecting IRTA5 or for detecting IRT A3, as well as methods for treating various B cell malignancies. Methods are disclosed for assessing the efficacy of a therapy for an autoimmune disease. |